T6381

Amifostine trihydrate (WR2721) is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin.

BTK-IN-7 is a selective and potent BTK inhibitor with an IC50 value of 4.0 nM. BTK-IN-7 exhibits high selectivity at both the enzymatic (ITK>250-fold, EGFR>2500-fold) and cellular levels (ITK>227-fold, EGFR27-fold). BTK-IN-7 exhibits high high antitumor effect.

EPI-7170 is a ralaniten analogue and a potent antagonist of the androgen receptor N-terminal structural domain, blocking the transcriptional activity of the full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 exhibits antitumor activity against enzalutamide resistant debulking resistant prostate cancer (CRPC).

MrgprX2 antagonist-8 is an MrgprX2 antagonist that can be used to study inflammatory diseases.

HIV-1 inhibitor-39 is a potent inhibitor of HIV-1 (EC50>112.88 μM). HIV-1 inhibitor-39 has anti-RT (HIV-1 reverse transcriptase) effect (IC50: 15.75 μM). HIV-1 inhibitor-39 exhibits cytotoxicity against MT-4 cells (CC50: 112.9 μM).

IDO2-IN-1 is a potent, orally active indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor, exhibiting an IC50 value of 112 nM. It is applicable in research related to inflammatory autoimmunity [1].

Filgotinib (maleate) is a selective, orally active JAK1 inhibitor that effectively inhibits the activity of JAK1 (IC50: 10 nM), JAK2 (IC50: 28 nM), JAK3 (IC50: 810 nM) and TYK2 (IC50: 116 nM). maleate) can be used to study rheumatoid arthritis (RA) and Crohn's disease.

FGFR1 inhibitor-6 is a potent FGFR1 inhibitor (IC50: 16.31 nM) with cytotoxic activity, capable of blocking the cell cycle in pro-G1 and G2/M phases, and inducing apoptosis.

Axl-IN-5 (compound 1) is an AXL inhibitor with an IC50 of 283 nM, demonstrating anticancer activity.

Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation.

Domperidone (R33812) monomaleate is a selective, orally active dopamine-2 receptor antagonist that affects the chemoreceptor trigger zone and motor function in the stomach and small intestine, and has antiemetic and prokinetic effects. Domperidone monomaleate is an antiemetic and prokinetic agent.